Lisa A. Carey, MD, on the CALGB/Alliance 40603 Trial
2014 San Antonio Breast Cancer SymposiumLisa A. Carey, MD, of the UNC Lineberger Comprehensive Cancer Center, addresses further analysis of data from abstract S4-05, “Impact of intrinsic subtype by PAM50 and other gene signatures on pathologic complete response rates in triple-negative breast cancer after neoadjuvant chemotherapy with or without carboplatin or bevacizumab: CALGB 40603/150709,” presented by William M. Sikov, MD.
Related Videos
William M. Sikov, MD, on the CALGB 40603 Trial
William M. Sikov, MD, of Women and Infants Hospital, discusses abstract S4-05, ...
Ismail Jatoi, MD, PhD, FACS, and Clifford A. Hudis, MD, FACS, Discuss the SOFT Trial
Ismail Jatoi, MD, PhD, FACS, and Clifford A. Hudis, MD, FACS, discuss the role of ovarian suppression and hormonal therapy in premenopausal women.
Larry Wickerham, MD, and Harry D. Bear, MD, PhD, on NSABP Neoadjuvant Chemotherapy Trials
Larry Wickerham, MD, and Harry D. Bear, MD, PhD, discuss three clinical trials:
• B-40, the only study to combine neoadjuvant and adjuvant chemoth...
Harry D. Bear, MD, PhD, on the NSABP B-51/RTOG 1304 Trial
Harry D. Bear, MD, PhD, of Massey Cancer Center, discusses abstract OT1-3-02, “...
Hope S. Rugo, MD, on the Phase II FIRST Study
Hope S. Rugo, MD, of the University of California, San Francisco, discusses abstract S6-04,
